A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00332462
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00330317
- Locations
- 🇬🇧
Novartis Investigative Site, West Smithfield, United Kingdom
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00329940
- Locations
- 🇫🇷
Novartis Investigative Site, Saint Cloud, France
Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2008-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT00324025
- Locations
- 🇺🇸
University of Alabama School of Medicine, Birmingham, Alabama, United States
🇺🇸Department of Medicine/Infectious Disease, MC 7881, University of Texas Health Science Center, San Antonio, Texas, United States
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 416
- Registration Number
- NCT00320710
- Locations
- 🇺🇸
Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸U of Pittsburgh Cancer Institute Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Frederick Memorial Hospital, Frederick, Maryland, United States
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 342
- Registration Number
- NCT00311753
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
- Conditions
- Interventions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1179
- Registration Number
- NCT00306787
- Locations
- 🇺🇸
Providence Clinical Research, Burbank, California, United States
🇺🇸Women's Medical Research Group, LLC, Clearwater, Florida, United States
🇺🇸UNC Clinical Research., Raleigh, North Carolina, United States
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT00304525
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology, Baltimore, Maryland, United States
🇺🇸Georgia Regents University Cancer Clinical Research Unit, Augusta, Georgia, United States
🇺🇸University of Pennsylvania Health System Dept of Hospital of UnivofPenn, Philadelphia, Pennsylvania, United States
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 184
- Registration Number
- NCT00303329
- Locations
- 🇺🇸
Childres's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Stanford Hospital, Stanford, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT00303251
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer, Houston, Texas, United States